Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cevidoplenib - Genosco

Next Previous
X
Search
Drug Profile

Cevidoplenib - Genosco

Alternative Names: Mesylate salt of SKI-O-592; SKI O 703

Latest Information Update: 25 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genosco
  • Developer Genosco; Oscotec
  • Class Anti-inflammatories; Antirheumatics; Small molecules
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Idiopathic thrombocytopenic purpura; Rheumatoid arthritis
  • Preclinical Antiphospholipid syndrome
  • No development reported Systemic lupus erythematosus

Most Recent Events

  • 25 Mar 2024 Cevidoplenib - Genosco is available for licensing as of 21 Mar 2024.
  • 21 Mar 2024 Cevidoplenib receives Orphan Drug status for Idiopathic thrombocytopenic purpura in USA
  • 16 Jun 2023 Cevidoplenib is still in phase trials for Rheumatoid arthritis in US, Russia, Czechia, Poland, Ukraine (Genosco Pipeline, June 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top